The main treatment for heart failure is etiological treatment.Because heart failure is the ultimate state of the heart, the causes of heart failure are different.Some people may have hyperthyroidism induced heart failure, and the treatment plan is to actively correct hyperthyroidism.Some people because arrhythmia causes tachycardia, cardiomyopathy, control arrhythmia, heart failure will improve naturally.There are still some people who have heart failure caused by ischemic heart disease. They need coronary angiography to actively change the state of heart ischemia, and heart failure can be recovered to a certain extent.There are other diseases, so the etiology of heart failure is important.If heart failure occurs, take active medication.Above all, want to use the therapeutics of heart failure normatively, strong heart, diuresis, dilate blood-vessel is a few treatment means to heart failure acute period, can alleviate improve the symptom of the patient.Chronic treatment of heart failure requires the long-term use of ACEI or ARB, beta blockers and diuretic drugs to reduce the length of hospital stay in patients with heart failure and improve their quality of life, as well as three-chamber pacemaker implantation and heart transplantation.
This report contains market size and forecasts of Heart Failure Treatment in Global, including the following market information:
Global Heart Failure Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Heart Failure Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Drug Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Heart Failure Treatment include Pfizer, Novartis, Merck, Sanofi, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Amgen and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Heart Failure Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Heart Failure Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Heart Failure Treatment Market Segment Percentages, by Type, 2021 (%)
Drug Treatment
Surgical Treatment
Global Heart Failure Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Heart Failure Treatment Market Segment Percentages, by Application, 2021 (%)
Acute Heart Failure
Chronic Heart Failure
Global Heart Failure Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Heart Failure Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Heart Failure Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Heart Failure Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Merck
Sanofi
Johnson & Johnson
AstraZeneca
GlaxoSmithKline
Amgen
Bayer
BMS
Cardiorentis
Cytokinetics
Ono Pharmaceuticals
Mylan
NCPC
Xinhua Group
Xudong Haipu Pharmaceutical